{"id":"cg400549","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"HDAC6 inhibition leads to accumulation of acetylated alpha-tubulin and aggresome formation, which enhances the clearance of protein aggregates implicated in neurodegenerative diseases. Additionally, HDAC6 inhibition can modulate T-cell function and enhance anti-tumor immunity, making it relevant for both neurological and oncological indications.","oneSentence":"CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:25:41.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Peripheral T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT01593761","phase":"PHASE2","title":"Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2012-06","conditions":"Skin Infection","enrollment":20},{"nctId":"NCT01085578","phase":"PHASE1","title":"CG400549 Single Ascending Dose Study","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2009-10","conditions":"Healthy","enrollment":18},{"nctId":"NCT01848470","phase":"PHASE1","title":"Multiple Ascending Doses Study of CG400549","status":"COMPLETED","sponsor":"CrystalGenomics, Inc.","startDate":"2010-05","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cohort 3"],"phase":"phase_2","status":"active","brandName":"CG400549","genericName":"CG400549","companyName":"CrystalGenomics, Inc.","companyId":"crystalgenomics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CG400549 is a selective inhibitor of histone deacetylase 6 (HDAC6) that promotes the degradation of misfolded proteins and modulates immune responses. Used for Multiple myeloma, Peripheral T-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}